Market Overview:
The global dermatomycoses drug market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of fungal infections, rising awareness about available treatment options, and growing demand for better-quality drugs. Based on type, the global dermatomycoses drug market is segmented into BB-2603, clotrimazole, dapaconazole, and others. Clotrimazole held the largest share of this market in 2017 and is expected to maintain its dominance during the forecast period. This can be attributed to its high efficacy against various types of fungi and wide availability across regions. Based on application, the global dermatomycoses drug market is segmented into hospital pharmacies, clinic pharmacies, and others (including retail pharmacies). Clinic pharmacies held a major share of this market in 2017 owing to their large customer base as well as increasing demand for better-quality drugs by patients.
Product Definition:
Dermatomycoses is a medical term for a fungal infection of the skin. It can cause redness, itching, scaling, and in some cases blisters or sores. Some types of dermatomycoses are more serious than others and may require treatment with prescription medication.
BB-2603:
BB-2603 is a topical corticosteroid used for the treatment of dermatomycosis. It belongs to the family of drugs known as betamethasone dipropionate (BD). BD is commonly prescribed for skin conditions like eczema, psoriasis and dermatitis. BB- 2603 has recently gained popularity due to its use in treating actinic keratosis and squamous cell carcinoma.
Clotrimazole:
Clotrimazole is an anti-fungal medication used for the treatment of athlete's foot, jock itch, ringworm, and other fungal infections of the skin. It works by killing the fungi that cause infection. The drug has a wide spectrum of activity against dermatophytes including tinea cruris (jock itch), tinea corporis (athlete’s foot), and tinea manus (ringworm).
Application Insights:
The others segment dominated the market for dermato mycoses and held the largest revenue share of over 60.0% in 2017. The application of dermablockers is expected to witness a high growth rate during the forecast period owing to their ability to treat chronic fungal infections that have resisted other treatment methods such as antifungal creams and oral medications.
Clinic-based applications are anticipated to exhibit a higher CAGR than hospital-based applications during the forecast period due to increasing awareness about these skin diseases among patients, resulting in increased utilization of these drugs at clinics across countries such as Germany, U.K.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing prevalence of dermatomycoses and rising awareness about treatment options. Moreover, availability of these drugs through commercialized brands and higher healthcare expenditure are some other factors contributing toward growth in this region.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to high unmet clinical needs coupled with growing disposable income levels among patients & their families resulting in better access to medical care facilities especially for Dermatomycosis diagnosis & treatment.
Growth Factors:
- Increasing incidence of dermatomycoses
- Growing awareness about the available treatment options for dermatomycoses
- Rising demand for better and more effective treatments for dermatomycoses
- Technological advancements in the field of dermatology
- Growing number of clinical studies on new therapies for treating dermatomycoses
Scope Of The Report
Report Attributes
Report Details
Report Title
Dermatomycoses Drug Market Research Report
By Type
BB-2603, Clotrimazole, Dapaconazole, Others
By Application
Hospital, Clinic, Others
By Companies
Anacor Pharmaceuticals Inc, Biolab Farmaceutica Ltda, Blueberry Therapeutics Ltd, Daewoong Pharmaceutical Co Ltd, Dermala Inc, Helix BioMedix Inc, Novan Inc, Sol-Gel Technologies Ltd, TGV-Laboratories, Viamet Pharmaceuticals Inc, Vyome Biosciences Pvt Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
210
Number of Tables & Figures
147
Customization Available
Yes, the report can be customized as per your need.
Global Dermatomycoses Drug Market Report Segments:
The global Dermatomycoses Drug market is segmented on the basis of:
Types
BB-2603, Clotrimazole, Dapaconazole, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Anacor Pharmaceuticals Inc
- Biolab Farmaceutica Ltda
- Blueberry Therapeutics Ltd
- Daewoong Pharmaceutical Co Ltd
- Dermala Inc
- Helix BioMedix Inc
- Novan Inc
- Sol-Gel Technologies Ltd
- TGV-Laboratories
- Viamet Pharmaceuticals Inc
- Vyome Biosciences Pvt Ltd
Highlights of The Dermatomycoses Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- BB-2603
- Clotrimazole
- Dapaconazole
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dermatomycoses Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Dermatomycoses is a group of fungal infections that affect the skin. These infections can cause red, itchy, and blistering skin lesions. Some dermatomycoses are more serious and can lead to death if not treated quickly. Dermatomycoses drugs are medications used to treat these infections.
Some of the major players in the dermatomycoses drug market are Anacor Pharmaceuticals Inc, Biolab Farmaceutica Ltda, Blueberry Therapeutics Ltd, Daewoong Pharmaceutical Co Ltd, Dermala Inc, Helix BioMedix Inc, Novan Inc, Sol-Gel Technologies Ltd, TGV-Laboratories, Viamet Pharmaceuticals Inc, Vyome Biosciences Pvt Ltd.
The dermatomycoses drug market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Dermatomycoses Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Dermatomycoses Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Dermatomycoses Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Dermatomycoses Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Dermatomycoses Drug Market Size & Forecast, 2018-2028
4.5.1 Dermatomycoses Drug Market Size and Y-o-Y Growth
4.5.2 Dermatomycoses Drug Market Absolute $ Opportunity
Chapter 5 Global Dermatomycoses Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Dermatomycoses Drug Market Size Forecast by Type
5.2.1 BB-2603
5.2.2 Clotrimazole
5.2.3 Dapaconazole
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Dermatomycoses Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Dermatomycoses Drug Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Dermatomycoses Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Dermatomycoses Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Dermatomycoses Drug Analysis and Forecast
9.1 Introduction
9.2 North America Dermatomycoses Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Dermatomycoses Drug Market Size Forecast by Type
9.6.1 BB-2603
9.6.2 Clotrimazole
9.6.3 Dapaconazole
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Dermatomycoses Drug Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Dermatomycoses Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Dermatomycoses Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Dermatomycoses Drug Market Size Forecast by Type
10.6.1 BB-2603
10.6.2 Clotrimazole
10.6.3 Dapaconazole
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Dermatomycoses Drug Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Dermatomycoses Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Dermatomycoses Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Dermatomycoses Drug Market Size Forecast by Type
11.6.1 BB-2603
11.6.2 Clotrimazole
11.6.3 Dapaconazole
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Dermatomycoses Drug Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Dermatomycoses Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Dermatomycoses Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Dermatomycoses Drug Market Size Forecast by Type
12.6.1 BB-2603
12.6.2 Clotrimazole
12.6.3 Dapaconazole
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Dermatomycoses Drug Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Dermatomycoses Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Dermatomycoses Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Dermatomycoses Drug Market Size Forecast by Type
13.6.1 BB-2603
13.6.2 Clotrimazole
13.6.3 Dapaconazole
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Dermatomycoses Drug Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Dermatomycoses Drug Market: Competitive Dashboard
14.2 Global Dermatomycoses Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Anacor Pharmaceuticals Inc
14.3.2 Biolab Farmaceutica Ltda
14.3.3 Blueberry Therapeutics Ltd
14.3.4 Daewoong Pharmaceutical Co Ltd
14.3.5 Dermala Inc
14.3.6 Helix BioMedix Inc
14.3.7 Novan Inc
14.3.8 Sol-Gel Technologies Ltd
14.3.9 TGV-Laboratories
14.3.10 Viamet Pharmaceuticals Inc
14.3.11 Vyome Biosciences Pvt Ltd
